Business Description
bioXXmed AG
ISIN : DE000A4BGGE4
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 87.57 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -185.02 | |||||
Beneish M-Score | -171.35 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.4 | |||||
3-Year EBITDA Growth Rate | 30 | |||||
3-Year EPS without NRI Growth Rate | 29.1 | |||||
3-Year FCF Growth Rate | 29.7 | |||||
3-Year Book Growth Rate | -74.3 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.19 | |||||
Quick Ratio | 7.19 | |||||
Cash Ratio | 6.45 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.1 | |||||
Shareholder Yield % | 58.69 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4976.47 | |||||
Net Margin % | -123229.41 | |||||
FCF Margin % | -4300 | |||||
ROE % | -146.17 | |||||
ROA % | -144.05 | |||||
ROIC % | -6.35 | |||||
3-Year ROIIC % | -4.82 | |||||
ROC (Joel Greenblatt) % | -299842.86 | |||||
ROCE % | -144.92 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 40.5 | |||||
PB Ratio | 1.49 | |||||
Price-to-Tangible-Book | 1.5 | |||||
EV-to-EBITDA | -0.45 | |||||
EV-to-Revenue | 20.77 | |||||
EV-to-FCF | -0.13 | |||||
Price-to-Net-Current-Asset-Value | 1.5 | |||||
Price-to-Net-Cash | 1.76 | |||||
FCF Yield % | -76.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
bioXXmed AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.017 | ||
EPS (TTM) (€) | -36.277 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 159.5 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 159.5 - 159.5 | ||
Shares Outstanding (Mil) | 0.58 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
bioXXmed AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
bioXXmed AG Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
bioXXmed AG Frequently Asked Questions
What is bioXXmed AG(CHIX:T5O0d)'s stock price today?
When is next earnings date of bioXXmed AG(CHIX:T5O0d)?
Does bioXXmed AG(CHIX:T5O0d) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |